BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hemperly A, Vande Casteele N. Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease. Clin Pharmacokinet 2018;57:929-42. [PMID: 29330783 DOI: 10.1007/s40262-017-0627-0] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 13.3] [Reference Citation Analysis]
Number Citing Articles
1 Mukherjee A, Tsuchiwata S, Nicholas T, Cook JA, Modesto I, Su C, D'Haens GR, Sandborn WJ. Exposure-Response Characterization of Tofacitinib Efficacy in Moderate to Severe Ulcerative Colitis: Results From Phase II and Phase III Induction and Maintenance Studies. Clin Pharmacol Ther 2022;112:90-100. [PMID: 35380740 DOI: 10.1002/cpt.2601] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Marcantonio DH, Matteson A, Presler M, Burke JM, Hagen DR, Hua F, Apgar JF. Early Feasibility Assessment: A Method for Accurately Predicting Biotherapeutic Dosing to Inform Early Drug Discovery Decisions. Front Pharmacol 2022;13:864768. [PMID: 35754500 DOI: 10.3389/fphar.2022.864768] [Reference Citation Analysis]
3 Cao WT, Huang R, Liu S, Fan YH, Xu MS, Xu Y, Ni H. Infliximab trough level combined with inflammatory biomarkers predict long-term endoscopic outcomes in Crohn’s disease under infliximab therapy. World J Gastroenterol 2022; 28(23): 2582-2596 [DOI: 10.3748/wjg.v28.i23.2582] [Reference Citation Analysis]
4 Zhou Z, Zhang Y, Pan Y, Yang X, Li L, Gao C, He C. A Novel Neutrophil-Based Biomarker to Monitor Disease Activity and Predict Response to Infliximab Therapy in Patients With Ulcerative Colitis. Front Med (Lausanne) 2022;9:872831. [PMID: 35572985 DOI: 10.3389/fmed.2022.872831] [Reference Citation Analysis]
5 Ferretti F, Cannatelli R, Monico MC, Maconi G, Ardizzone S. An Update on Current Pharmacotherapeutic Options for the Treatment of Ulcerative Colitis. J Clin Med 2022;11:2302. [PMID: 35566428 DOI: 10.3390/jcm11092302] [Reference Citation Analysis]
6 Iria I, Soares RRG, Brás EJS, Chu V, Gonçalves J, Conde JP. Accurate and rapid microfluidic ELISA to monitor Infliximab titers in patients with inflammatory bowel diseases. Analyst 2022;147:480-8. [PMID: 35023516 DOI: 10.1039/d1an01810h] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Alijotas-Reig J, Esteve-Valverde E, Anunciación-Llunell A, Marques-Soares J, Pardos-Gea J, Miró-Mur F. Pathogenesis, Diagnosis and Management of Obstetric Antiphospholipid Syndrome: A Comprehensive Review. J Clin Med 2022;11:675. [PMID: 35160128 DOI: 10.3390/jcm11030675] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
8 Orts B, Gutierrez A, Madero L, Sempere L, Frances R, Zapater P. Clinical and Immunological Factors Associated with Recommended Trough Levels of Adalimumab and Infliximab in Patients with Crohn's Disease. Front Pharmacol 2021;12:795272. [PMID: 35046819 DOI: 10.3389/fphar.2021.795272] [Reference Citation Analysis]
9 Huang Y, Yao D, Guo F, Zhou Z, Li Y. Preoperative Anti-TNF Therapy is Associated with a Shorter Length of Resected Bowel in Patients Undergoing Ileocolic Resection for Crohn's Disease. J Invest Surg 2022;:1-9. [PMID: 34983280 DOI: 10.1080/08941939.2021.2023713] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Zhang T, Ma C, Zhang Z, Zhang H, Hu H. NF-κB signaling in inflammation and cancer. MedComm (2020) 2021;2:618-53. [PMID: 34977871 DOI: 10.1002/mco2.104] [Cited by in Crossref: 1] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
11 Maguire AD, Bethea JR, Kerr BJ. TNFα in MS and Its Animal Models: Implications for Chronic Pain in the Disease. Front Neurol 2021;12:780876. [PMID: 34938263 DOI: 10.3389/fneur.2021.780876] [Reference Citation Analysis]
12 Fournier KA, Dwyer PA, Vessey JA, Shea J, Pratt P. The Efficacy of Antihistamines in Preventing Reactions to Infliximab in Patients With Crohn Disease/Ulcerative Colitis: A Review of the Evidence. Gastroenterol Nurs 2020;43:345-9. [PMID: 33003021 DOI: 10.1097/SGA.0000000000000482] [Reference Citation Analysis]
13 Zou F, Faleck D, Thomas A, Harris J, Satish D, Wang X, Charabaty A, Ernstoff MS, Glitza Oliva IC, Hanauer S, McQuade J, Obeid M, Shah A, Richards DM, Sharon E, Wolchok J, Thompson J, Wang Y. Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study. J Immunother Cancer 2021;9:e003277. [PMID: 34789551 DOI: 10.1136/jitc-2021-003277] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
14 Shirley M. Subcutaneous Infliximab, CT-P13 SC: A Profile of Its Use in the EU. Clin Drug Investig 2021;41:1099-107. [PMID: 34727347 DOI: 10.1007/s40261-021-01093-8] [Reference Citation Analysis]
15 Lu S, Wang Y, Liu J. TNF-α signaling in non-alcoholic steatohepatitis and targeted therapies. J Genet Genomics 2021:S1673-8527(21)00337-4. [PMID: 34757037 DOI: 10.1016/j.jgg.2021.09.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
16 Schräpel C, Kovar L, Selzer D, Hofmann U, Tran F, Reinisch W, Schwab M, Lehr T. External Model Performance Evaluation of Twelve Infliximab Population Pharmacokinetic Models in Patients with Inflammatory Bowel Disease. Pharmaceutics 2021;13:1368. [PMID: 34575443 DOI: 10.3390/pharmaceutics13091368] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Yueying C, Jing F, Tian Y, Yuqi Q, Jun S. Bioelectrical impedance analysis-based nomogram construction for predicting secondary loss of response to infliximab in bio-naïve Crohn's disease patients. Biomed Pharmacother 2021;142:112076. [PMID: 34449314 DOI: 10.1016/j.biopha.2021.112076] [Reference Citation Analysis]
18 Marquez-Megias S, Ramon-Lopez A, Más-Serrano P, Diaz-Gonzalez M, Candela-Boix MR, Nalda-Molina R. Evaluation of the Predictive Performance of Population Pharmacokinetic Models of Adalimumab in Patients with Inflammatory Bowel Disease. Pharmaceutics 2021;13:1244. [PMID: 34452204 DOI: 10.3390/pharmaceutics13081244] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Moreno LO, Fernández-tomé S, Abalo R. Biological Treatments in Inflammatory Bowel Disease: A Complex Mix of Mechanisms and Actions. Biologics 2021;1:189-210. [DOI: 10.3390/biologics1020012] [Reference Citation Analysis]
20 deBruyn JCC, Jacobson K, El-Matary W, Wine E, Carroll MW, Goedhart C, Panaccione R, Wrobel IT, Huynh HQ. Early Serum Infliximab Levels in Pediatric Ulcerative Colitis. Front Pediatr 2021;9:668978. [PMID: 34395336 DOI: 10.3389/fped.2021.668978] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Hong JG, Levy J, Stokar E. Henoch-Schönlein purpura and crohn's disease: Expanding the range of association in pediatric patients. Clin J Gastroenterol 2021;14:1392-5. [PMID: 34114169 DOI: 10.1007/s12328-021-01456-w] [Reference Citation Analysis]
22 Bhat S, Qazi T, Farraye FA. Managing infliximab infusions after a drug holiday. Am J Health Syst Pharm 2021:zxab234. [PMID: 34059875 DOI: 10.1093/ajhp/zxab234] [Reference Citation Analysis]
23 Adamina M, Fiorino G. At the crossroads of caution and intervention: anti-TNF therapy prior to elective CD surgery Authors' Reply to: "Anti-TNF therapy before intestinal surgery for Crohn's disease and the risks of postoperative complications". J Crohns Colitis 2021:jjab092. [PMID: 33999192 DOI: 10.1093/ecco-jcc/jjab092] [Reference Citation Analysis]
24 Tong X, Zheng Y, Li Y, Xiong Y, Chen D. Soluble ligands as drug targets for treatment of inflammatory bowel disease. Pharmacol Ther 2021;226:107859. [PMID: 33895184 DOI: 10.1016/j.pharmthera.2021.107859] [Reference Citation Analysis]
25 Pospisilova K, Siroka J, Karaskova E, Hradsky O, Lerchova T, Zarubova K, Copova I, Gonsorcikova L, Velganova-Veghova M, Francova I, Urbanek L, Geryk M, Mihal V, Bronsky J. Is It Useful to Monitor Thiopurine Metabolites in Pediatric Patients with Crohn's Disease on Combination Therapy? A Multicenter Prospective Observational Study. Paediatr Drugs 2021;23:183-94. [PMID: 33709340 DOI: 10.1007/s40272-021-00439-1] [Reference Citation Analysis]
26 Sparrow MP, Papamichael K, Ward MG, Riviere P, Laharie D, Paul S, Roblin X. Therapeutic Drug Monitoring of Biologics During Induction to Prevent Primary Non-Response. J Crohns Colitis 2020;14:542-56. [PMID: 31549158 DOI: 10.1093/ecco-jcc/jjz162] [Cited by in Crossref: 16] [Cited by in F6Publishing: 23] [Article Influence: 16.0] [Reference Citation Analysis]
27 Di Paolo A, Luci G. Personalized Medicine of Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacogenetics, Therapeutic Drug Monitoring, and Beyond. Front Pharmacol 2020;11:610806. [PMID: 33628180 DOI: 10.3389/fphar.2020.610806] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
28 Li JR, Ling FM, Chen YD, Xu MY, Zhu LR. Treatment of acute severe ulcerative colitis. Shijie Huaren Xiaohua Zazhi 2021; 29(2): 87-92 [DOI: 10.11569/wcjd.v29.i2.87] [Reference Citation Analysis]
29 Zhao J, Lu Q, Liu Y, Shi Z, Hu L, Zeng Z, Tu Y, Xiao Z, Xu Q. Th17 Cells in Inflammatory Bowel Disease: Cytokines, Plasticity, and Therapies. J Immunol Res 2021;2021:8816041. [PMID: 33553436 DOI: 10.1155/2021/8816041] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
30 Krusiński A, Grzywa-Celińska A, Szewczyk K, Grzycka-Kowalczyk L, Emeryk-Maksymiuk J, Milanowski J. Various Forms of Tuberculosis in Patients with Inflammatory Bowel Diseases Treated with Biological Agents. Int J Inflam 2021;2021:6284987. [PMID: 33489084 DOI: 10.1155/2021/6284987] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Bauman LE, Xiong Y, Mizuno T, Minar P, Fukuda T, Dong M, Rosen MJ, Vinks AA. Improved Population Pharmacokinetic Model for Predicting Optimized Infliximab Exposure in Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis 2020;26:429-39. [PMID: 31287855 DOI: 10.1093/ibd/izz143] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 10.5] [Reference Citation Analysis]
32 Grisic AM, Eser A, Huisinga W, Reinisch W, Kloft C. Quantitative relationship between infliximab exposure and inhibition of C-reactive protein synthesis to support inflammatory bowel disease management. Br J Clin Pharmacol 2021;87:2374-84. [PMID: 33184852 DOI: 10.1111/bcp.14648] [Reference Citation Analysis]
33 Tang J, Zhang CB, Lyu KS, Jin ZM, Guan SX, You N, Huang M, Wang XD, Gao X. Association of polymorphisms in C1orf106, IL1RN, and IL10 with post-induction infliximab trough level in Crohn's disease patients. Gastroenterol Rep (Oxf) 2020;8:367-73. [PMID: 33163192 DOI: 10.1093/gastro/goz056] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
34 Alsoud D, Vermeire S, Verstockt B. Monitoring vedolizumab and ustekinumab drug levels in patients with inflammatory bowel disease: hype or hope?Curr Opin Pharmacol. 2020;55:17-30. [PMID: 33039940 DOI: 10.1016/j.coph.2020.09.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
35 Eser A, Reinisch W, Schreiber S, Ahmad T, Boulos S, Mould DR. Increased Induction Infliximab Clearance Predicts Early Antidrug Antibody Detection. J Clin Pharmacol 2021;61:224-33. [PMID: 32905628 DOI: 10.1002/jcph.1732] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
36 Argollo M, Kotze PG, Kakkadasam P, D'Haens G. Optimizing biologic therapy in IBD: how essential is therapeutic drug monitoring? Nat Rev Gastroenterol Hepatol 2020;17:702-10. [PMID: 32879465 DOI: 10.1038/s41575-020-0352-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 12.0] [Reference Citation Analysis]
37 Oftedal BE, Wolff ASB. New era of therapy for endocrine autoimmune disorders. Scand J Immunol 2020;92:e12961. [PMID: 32853446 DOI: 10.1111/sji.12961] [Reference Citation Analysis]
38 Jongsma MME, Winter DA, Huynh HQ, Norsa L, Hussey S, Kolho KL, Bronsky J, Assa A, Cohen S, Lev-Tzion R, Van Biervliet S, Rizopoulos D, de Meij TGJ, Shouval DS, Wine E, Wolters VM, Martinez-Vinson C, de Ridder L; Paediatric IBD Porto Group of ESPGHAN. Infliximab in young paediatric IBD patients: it is all about the dosing. Eur J Pediatr 2020;179:1935-44. [PMID: 32813123 DOI: 10.1007/s00431-020-03750-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
39 Decara J, Rivera P, López-Gambero AJ, Serrano A, Pavón FJ, Baixeras E, Rodríguez de Fonseca F, Suárez J. Peroxisome Proliferator-Activated Receptors: Experimental Targeting for the Treatment of Inflammatory Bowel Diseases. Front Pharmacol 2020;11:730. [PMID: 32536865 DOI: 10.3389/fphar.2020.00730] [Cited by in Crossref: 8] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
40 Al-Ani AH, Prentice RE, Rentsch CA, Johnson D, Ardalan Z, Heerasing N, Garg M, Campbell S, Sasadeusz J, Macrae FA, Ng SC, Rubin DT, Christensen B. Review article: prevention, diagnosis and management of COVID-19 in the IBD patient. Aliment Pharmacol Ther 2020;52:54-72. [PMID: 32348598 DOI: 10.1111/apt.15779] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 26.5] [Reference Citation Analysis]
41 Hansen TM, Targownik LE, Karimuddin A, Leung Y. Management of Biological Therapy Before Elective Inflammatory Bowel Disease Surgeries. Inflamm Bowel Dis 2019;25:1613-20. [PMID: 30794289 DOI: 10.1093/ibd/izz002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
42 Lee Y, Mansur RB, Brietzke E, Carmona NE, Subramaniapillai M, Pan Z, Shekotikhina M, Rosenblat JD, Suppes T, Cosgrove VE, Kramer NE, McIntyre RS. Efficacy of adjunctive infliximab vs. placebo in the treatment of anhedonia in bipolar I/II depression. Brain Behav Immun 2020;88:631-9. [PMID: 32380271 DOI: 10.1016/j.bbi.2020.04.063] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
43 Lefevre PLC, Shackelton LM, Vande Casteele N. Factors Influencing Drug Disposition of Monoclonal Antibodies in Inflammatory Bowel Disease: Implications for Personalized Medicine. BioDrugs 2019;33:453-68. [PMID: 31301024 DOI: 10.1007/s40259-019-00366-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
44 Gibson DJ, Ward MG, Rentsch C, Friedman AB, Taylor KM, Sparrow MP, Gibson PR. Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2020;51:612-28. [DOI: 10.1111/apt.15643] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 13.5] [Reference Citation Analysis]
45 Romano C, Esposito S, Ferrara R, Cuomo G. Choosing the most appropriate biologic therapy for Crohn’s disease according to concomitant extra-intestinal manifestations, comorbidities, or physiologic conditions. Expert Opinion on Biological Therapy 2020;20:49-62. [DOI: 10.1080/14712598.2020.1689953] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
46 Grover Z, Alex G. Management of inflammatory bowel disease in children: It is time for an individualised approach. J Paediatr Child Health 2020;56:1677-84. [DOI: 10.1111/jpc.14652] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
47 Vande Casteele N, Jeyarajah J, Jairath V, Feagan BG, Sandborn WJ. Infliximab Exposure-Response Relationship and Thresholds Associated With Endoscopic Healing in Patients With Ulcerative Colitis. Clinical Gastroenterology and Hepatology 2019;17:1814-1821.e1. [DOI: 10.1016/j.cgh.2018.10.036] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 9.7] [Reference Citation Analysis]
48 Liefferinckx C, Minsart C, Cremer A, Amininejad L, Tafciu V, Quertinmont E, Tops S, Devière J, Gils A, van Gossum A, Franchimont D. Early vedolizumab trough levels at induction in inflammatory bowel disease patients with treatment failure during maintenance. Eur J Gastroenterol Hepatol 2019;31:478-85. [PMID: 30672828 DOI: 10.1097/MEG.0000000000001356] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 4.7] [Reference Citation Analysis]
49 Pouillon L, Vermeire S, Bossuyt P. Vedolizumab trough level monitoring in inflammatory bowel disease: a state-of-the-art overview. BMC Med 2019;17:89. [PMID: 31064370 DOI: 10.1186/s12916-019-1323-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 27] [Article Influence: 5.3] [Reference Citation Analysis]
50 Saito J, Yakuwa N, Kaneko K, Nakajima K, Takai C, Goto M, Yamatani A, Murashima A. Clinical application of the dried milk spot method for measuring tocilizumab concentrations in the breast milk of patients with rheumatoid arthritis. Int J Rheum Dis 2019;22:1130-7. [PMID: 30968569 DOI: 10.1111/1756-185X.13557] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
51 Liefferinckx C, Verstockt B, Gils A, Tops S, Van Moerkercke W, Vermeire S, Franchimont D. Impact of first-line infliximab on the pharmacokinetics of second-line vedolizumab in inflammatory bowel diseases. United European Gastroenterol J 2019;7:750-8. [PMID: 31316779 DOI: 10.1177/2050640619841538] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
52 Turkowski Y, Konnikov N, Mahalingam M. Necrotizing Granulomas in a Patient With Psoriasis and Sarcoidosis After Adalimumab-Medication-Induced Reaction or Reactivation of Latent Disease? Am J Dermatopathol 2019;41:661-6. [PMID: 30839343 DOI: 10.1097/DAD.0000000000001394] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
53 Tarnok A, Kiss Z, Kadenczki O, Veres G. Characteristics of biological therapy in pediatric patients with Crohn's disease. Expert Opin Biol Ther 2019;19:181-96. [PMID: 30601083 DOI: 10.1080/14712598.2019.1564034] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Cunha Neto F, Marton LT, de Marqui SV, Lima TA, Barbalho SM. Curcuminoids from Curcuma Longa: New adjuvants for the treatment of crohn's disease and ulcerative colitis? Crit Rev Food Sci Nutr 2019;59:2136-43. [PMID: 29565637 DOI: 10.1080/10408398.2018.1456403] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
55 Vande Casteele N, Oyamada J, Shimizu C, Best BM, Capparelli EV, Tremoulet AH, Burns JC. Infliximab Pharmacokinetics are Influenced by Intravenous Immunoglobulin Administration in Patients with Kawasaki Disease. Clin Pharmacokinet 2018;57:1593-601. [DOI: 10.1007/s40262-018-0653-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]